These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10577070)

  • 1. [Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Sep; 22(9):288-9. PubMed ID: 10577070
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1999 Aug; 41(1059):71-3. PubMed ID: 10603986
    [No Abstract]   [Full Text] [Related]  

  • 3. [When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
    MMW Fortschr Med; 2003 Mar; 145(10):59. PubMed ID: 12688034
    [No Abstract]   [Full Text] [Related]  

  • 4. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 5. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
    Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E
    Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036
    [No Abstract]   [Full Text] [Related]  

  • 6. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
    Zinman B
    Diabetes Obes Metab; 2001 Aug; 3 Suppl 1():S34-43. PubMed ID: 11685828
    [No Abstract]   [Full Text] [Related]  

  • 7. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA; Sautter M; Van Gaal LF; Jones NP
    Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
    MMW Fortschr Med; 2003 Dec; 145(50):54. PubMed ID: 14963975
    [No Abstract]   [Full Text] [Related]  

  • 9. [Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
    Reblin T; Seidel D; Stein D; Görtz A; Lander T
    MMW Fortschr Med; 2003 May; 145(19):41. PubMed ID: 12813977
    [No Abstract]   [Full Text] [Related]  

  • 10. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
    King AB
    Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
    [No Abstract]   [Full Text] [Related]  

  • 13. [Type 2 diabetes. How can the infarction risk be reduced?].
    MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921655
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rosiglitazone (BRL-49653)].
    Oka Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 16. Actos (pioglitazone): a new treatment for type 2 diabetes.
    Lawrence JM; Reckless JP
    Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rosiglitazone (BRL-49653)].
    Kameda N; Okuya S; Oka Y
    Nihon Rinsho; 2000 Feb; 58(2):401-4. PubMed ID: 10707565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
    Hanefeld M; Fischer S
    MMW Fortschr Med; 2003 Feb; 145(9):30-4. PubMed ID: 12666526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
    Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
    Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.